



This presentation and the accompanying slides (the "Presentation"), which have been prepared by Quick Heal Technologies Ltd. (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward-looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward-looking statements become materially incorrect in future or update any forward-looking statements made from time to time by or on behalf of the Company.

Quick Heal acknowledges the ownership rights of third parties to the intellectual property rights mentioned in this document. Other logos/trademarks mentioned in the presentation belongs to respective owners and used only for reference purpose.







Agenda

01

02

03

04



Industry Overview



Company Overview

The Quick Heal Advantage

ĝ ĝ ĝ

Q3FY22 Earnings Highlights

05

Q3FY22 Earnings






INDUSTRY OVERVIEW


Rapid digitization has enhanced need for greater cybersecurity investments
















20xMobile data usage (FY16 – FY21)



1.32b





Users engaged in social media

639m



Application downloads in 2020

30b




Average cost to subscriber per GB wireless data

Rs.**6.98**

Source: The Ministry of Electronics and Information Technology, TRAI, Government of India, Statista, Google report – Insights for Brands, KPMG Report – Fintech In India, India Data Diviner – Macquarie, Nokia MBIT, Goldman Sachs Investment Research – Portfolio Strategy Research (Sept 19, 2021)

Cyber attacks continue to grow in scale and sophistication





₹ 165 mln

The Average cost of a data breach in India.

An increase of **17.85%** from 2020

Source: Quick Heal Threat Report 2021

Source: IBM





Indian gamers lost Rs.7,894 on an average due to cyberattacks- The Mint (November 15, 2021)

Cybercrimes in India during pandemic have gone up by 500 per cent: CDS Gen Bipin Rawat – Economic times (November 12, 2021)

India 3rd in data breaches till Nov-Times of India (December 17, 2021)


Indian PM Modi's Twitter hacked with bitcoin tweet-BBC News (December 12, 2021)


Source: Reputed News Outlets

2021 Cyber threat landscape shows that...









Source: Segrite Annual Threat Report 2022

Source: Segrite Annual Threat Report 2022

Source: Quick Heal Annual Threat Report 2022



Cyber threat predictions for 2022 and beyond

01

'Karakurt' Extortion threat emerges focusing on data theft for ransom 02

Fileless Malware Infection likely to advance and escape security products detection 03

Rise of double and triple-vector extortion technique demanding money for encrypted files 04

Cobalt strike attacks gets more sophisticated with new features and MITRE framework

05

Rise in Covid-themebased attacks with the use of more sophisticated social engineering techniques 06

Increase in supply chain attacks leading to ransomware and other complex exploitations

07

Critical zero-day vulnerabilities on the rise

08

Rise in the new vulnerabilities on the server-side technologies

09

Rise of IoT attacks on vulnerable companion applications 10

Rise of social media credential stealer applications

11

Use of AI voice cloning tricks and Deepfake techniques to steel sensitive data

12

Rise of Ransomwareasa-Service attacks targeting critical sectors

13

Rise in Linux side vulnerabilities with the release of WSL feature 14

Resurrection of old vulnerabilities using ransomware via phishing emails and malicious files


15

Rise in targeted surveillance attacks with variants of different spywares

Source: Segrite Threat Predictions 2022

Quick Heal is well positioned to leverage its strengths to capture the future opportunities









COMPANY OVERVIEW

Company at a glance





Vision

To be the trusted global leader in securing the digital world

Mission


Secure our customers by providing innovative, most preferred and valued security solutions, services and knowledge

Protect information and interactions on all types of networks, devices & things globally

Build a healthy business and organization

Our journey





Over 25 years of simplifying security

Scripting a new success story In the cybersecurity industry

Quick Heal





₹ **652** mln Q3FY22 Revenue*







₹**201** mln Q3FY22 Revenue*















*Based on net revenues before adjusting for sales incentives

- India's first listed cybersecurity products company
- A "Make in India" product configured to secure countries, cities and companies
- Quick Heal undisputed leader in the retail segment
- Seqrite making inroads in the SMB & enterprise segment
- Quick Heal Security Labs a team of highly efficient security researchers, analysts and engineers leverages a combination of AI, cloud and patented technologies to deliver timely and advanced protection
- Solutions to secure across platforms

The Cash Cow: Anti Virus Business




- Over 25 years into existence
- Market leadership with over 30% in the Indian market
- Robust Sales & Distribution network in India

Revenue (INR Mn) 652 603 Q3FY20 Q3FY21 Q3FY22










Cybersecurity Startup incubated inhouse






- Incubated the enterprise cybersecurity through internal accruals
- Growth story for QH in the years to come
- Launching new products
- %Exports : ~18% of our Enterprise revenues
- Amount spent on R&D has been charged to P&L as per prudent accounting policies and good governance practices

ARR* of over INR 800 Mn

Shareholding Information



Shareholding structure – 31st December 2021



Shareholder Information (as on 31st December 2021)

NSE Ticker	QUICKHEAL
BSE Ticker	539678
Market Cap (INR mln)	14,350
% Free-float	27.08%
Free-float market cap (INR mln)	3,886
Total Debt (INR mln)	-
Cash & Cash Equivalents (INR mln)	3,275
Shares Outstanding	5.79,56,601
3M ADTV (Shares)*	1,94,919
3M ADTV (INR mln)*	45.6
Industry	IT Software Products


^{*}Source: NSE



Strong threat detection and prevention capabilities...









Powers **SIGNATURE-LESS** and **SIGNATURE-BASED** detections


Our best and the most innovative malware hunting engine brings together the best of the best!













...with State-of-the-Art Research & Development leading to Innovations

25+ years of experience coupled with vast distribution network across India has helped us understand security market and issues faced by millions of users in depth which has led to consistent introduction of innovative products and solutions for our customers






Committed to deliver exceptional



customer experience

- Multi-lingual end user support in English, Hindi and several other major regional Indian languages
 - 2 Availability of data sheets, product videos and manuals on website for providing information on technical specifications, installation guide, upgrade mechanisms
 - Release of various articles, technical papers, quarterly threat reports and conducting webinars in the area of security software



Experienced Board of Directors





Dr. Kailash Katkar MD & CEO

Drives the strategic direction for the company while nurturing a strong leadership team to drive its execution



Dr. Sanjay Katkar
Joint MD & CTO

Spearheads the creation and subsequent development of the core product technology



Mr. Shailesh Lakhani Non-Executive Director

Serves as the MD at Sequoia Capital India. Previously, he worked at Redknee's India subsidiary as the Managing Director



Mr. Amitabha Mukhopadhyay Independent Director

Over three decades of experience in corporate finance, legal and litigation, strategy and M&A. Served as the Group CFO of Thermax



Air Marshal (Retd) Bhushan Nilkanth Gokhale Independent Director

Served on the board of defense PSUs and adviser to government institutions. Appointed as Independent Security Advisor in Ministry of Home Affairs.



Mr. Mehul Savla Independent Director

Serves as Director for RippleWave Equity Advisors LLP. Previously worked at JP Morgan, ICICI Securities and SEBI



Ms. Apurva Joshi
Independent Director

Certified bank forensic accounting professional and anti – money laundering expert



Mr. Richard Stiennon Independent Director

Serves as Chief Research Analyst at IT-Harvest, and sits on the advisory boards of several start-ups. Has been the part of board of cybersecurity companies like Symantec, McAfee, Cisco, Microsoft and Trend Micro

...along with strong Management...





Dr. Kailash Katkar *MD & CEO*

Co-founder of the Company

Has been the driving force in growing Quick Heal Technologies since it's inception.

A proven leader with a profound proficiency in developing strong client relationships, passion for building outstanding teams and a disciplined focus on operations & execution of strategy.



Dr. Sanjay Katkar Joint MD & CTO

Co-founder of the Company

Leads the global technology strategy & is responsible for the core research & development of the products.

Has served as the Director of Association of Anti-Virus Researchers, Asia and is a distinguished speaker at various industry forums.

Holds Master's degree in Computer Science from the University of Pune.

...and seasoned Leadership team





Mr. Navin Sharma

Responsible for driving growth lead strategy through organic & inorganic channels.

Previously was the CFO with Sterlite Technologies for the technology business.

Navin has worked with RPG Group and Century Textiles and Industries Limited and brings vast experience in the areas of M&A, customer acquisition, financial planning and analysis and managing overseas operations.



Ms. Reetu Raina

Responsible for driving HR and steering the company's people operations, culture and recruitment initiatives.

Ms. Raina holds extensive industry experience and has worked across sectors such as Telecom, BFSI, and IT.

She has held leadership roles with domain-leading brands such as TATA, HDFC Bank, and Amdocs. She was the Head of HR at Sterlite Technologies.



Mr. Sanjay Agrawal

Responsible for driving the overall product vision and strategy in line with market expectations.

Sanjay is an entrepreneurial engineering and product leader with two decades of experience and proven success in building cybersecurity products for the global markets.

A computer engineering graduate from University of Illinois, Sanjay holds a Ph.D. and M.S. from Stanford University in Electrical Engineering and Computer Science (EECS).

...and seasoned Leadership team



Mr. Bibhuti Kar Head, R&D

Responsible for driving company's development efforts leading a team of talented engineering professionals and security researchers.

Bibhuti brings with him over two and a half decades of rich experience in the global high-tech industry.

An alumnus of IIT Kharagpur with a master's in ECE, he has worked on missile communication systems with DRDO.



Mr. Kuldeep Raina
Head, Global Enterprise Sales

Responsible for leading the enterprise and government sales strategy and managing the vertical on a global level.

Passionate technocrat with a rich flare for sales and ability to drive targets in dynamic business environment.

Over two decades of diverse sales experience including leadership roles in cybersecurity companies.





Mr. Deepak Mishra Head, Retail Sales

Responsible for enhancing market share and driving channel strategy for the retail brand.

Has extensive exposure in sales and distribution, channel management, and building a robust distribution to drive productivity and profitability.

Over two decades of experience in FMCG, Beverages, Telecom and IT Industries.

Strong brand recognition...



Certified and approved **by ICSA Labs** in 2021



Certified with
Advanced
Approved Endpoint
Protection by
AV-Test 2021





Best AV of 2020 at the 13th NCN Innovative Product Award 2021







Certified as 'Top

Product' for



Certified and approved **by ICSA Labs** in 2020



Certified as 'Top Product' for business users by 'AV-Test' in 2020



Certified as **'Top Product'** for consumers

by **'AV-Test'** in 2020



Segrite

'Best Performance 2018' award for its Endpoint Security Solution from AV-Test Institute in Germany 2019



Quick Heal Technologies

Recognized by

NASSCOM's DSCI

'Cybersecurity

in India' 2019

Product Pioneer

Granted Patent for Anti-Ransomware Technology 2019 U.S. Patent No. US20160378988A1

Ouick Heal

Technologies



Quick Heal Technologies

Granted Patent for its **Signatureless Behavior-based Detection Technology** 2019
U.S Patent No.
US20170124327A1

...backed by Certifications, Patents and...

International & ISO Certifications















Cybersecurity Product
Pioneer in India

Patented Technologies

USPTO 10,387,649

Signatureless Behaviour-based Detection Technology

USPTO 10,311,234

Anti-Ransomware technology

USPTO 8,973,136

System and method for protecting computer systems from malware attacks

USPTO 8,914,908

A completely automated computer implemented system and method for piracy control based on update requests

USPTO 8,347,389

System for protecting devices against virus attacks

USPTO 7,945,955

Virus detection in mobile devices having insufficient resources to execute virus detection software

Securing the future through our community initiatives







23,50,000+

Lives directly impacted since 2016

Cybersecurity

- Cybersecurity Awareness
- Cyber Shiksha for Suraksha
- Street Plays



1,00,000+

Lives impacted since 2020

Covid-19 Relief Initiatives

- Free immunity boosters medicines to frontline workers
- Organised health camps and assisted in the smooth functioning of Covid-19 centres
- Donated medical vans to NGOs to heal tribal population
- Distribution of food grains during lockdown
- Distribution of PPE kits to NGOs
- Donated to PM Cares Fund









45,000+

Lives directly impacted since 2016

Education

 Life Skills Education for underprivileged children











Quick Heal Academy to drive the next generation of cyber security experts





Popular Courses

- ✓ Cyber Security and Forensics
- ✓ Cyber Threat Intelligence
- ✓ Malware Analysis & Reverse Engineering
- √ Security Operations Centre (SOC)
- ✓ Electronic Crime Scene Investigation

Offerings



CORPORATE TRAINING



NEED-BASED TRAINING



WORKSHOPS & SEMINARS



CONNECTING CYBER ECO-SYSTEM

Academy Partners

Chitkara University

CHITKARA

MANAV RACHNA

W

Quantum

BSCI

A NASSCOM® Initiative

MoU with Chitkara University Introduced an additional stream in Cyber Security for the four-year Undergraduate program

Quantum University

MoU with Quantum University for a joint B.Tech (Hons.) with specialization in Cyber Security

Manav Rachna University

MoU with Manav Rachna University (MRU) for a joint B. Tech in Cyber Security & Threat Intelligence, programme

'Cyber Shikshaa Programme' an initiate of DSCI and Microsoft: Quick Heal as the training partner has targeted to train 5000 students across India creating cyber security awareness through online programme

Sage University

MoU with Sage University (Indore) for a joint B. Tech in Cyber Security programme

Parul University

MoU with Parul University, Vadodara for Joint B. Tech Programme (4 Years)





Q3FY22 Earnings Highlight







Q3FY22 Revenue at

₹796 mln

Up 14% from Q3FY21

Diluted EPS

Q3FY22 EPS at

2.45

Up 17% from Q3FY21

EBITDA



Q3FY22 EBITDA at

₹205 mln

Up 24% from Q3FY21

Retail at

₹652 mln

Up 8% from Q3FY21

PAT

Q3FY22 PAT at

₹143 mln

Up 6% from Q3FY21

Enterprise at

₹201 mln

Up 11% from Q3FY21

Q3FY22 Revenue split







Enterprise + Government 23.6%



Q3FY22 – Consolidated Performance Highlights








^{*}As per Ind AS

9MFY22 - Consolidated Performance Highlights





^{**}Note: There was a spill over of revenue of ₹ 300 mln from Q4FY20 in Q1FY21 due to non -availability of transport facilities due to lockdown

^{*}As per Ind AS

Q3FY22 Segment performance







Retail


Enterprise & Government


Revenue break-up





Licenses Sold Analysis





9MFY22 Segment performance







Retail


Enterprise & Government


Revenue break-up





Licenses Sold Analysis





Q3FY22 – Profitability statement





DARTICULARS (F min)		Standalone		C	onsolidated	
PARTICULARS (₹ mln)	Q3FY21	Q3FY22	% change	Q3FY21	Q3FY22	% change
Total Revenue	711.23	796.25	11.95%	698.75	796.16	13.94%
Direct Cost	26.18	32.42		26.39	32.40	
Gross Profit	685.05	763.83	11.50%	672.36	763.76	13.59%
Gross Margin	96.32%	95.93%	-39bps	96.22%	95.93%	-29bps
Operating Cost						
Research and Development (R&D)	170.09	213.04		170.09	213.04	
Sales and Marketing (S&M)	221.05	211.56		224.99	214.80	
General Administration (G&A)	136.45	134.77		112.65	131.12	
Total Expenditure	527.59	559.37	-6.02%	507.73	558.96	-10.09%
EBITDA	157.46	204.46	29.85%	164.63	204.80	24.40%
EBITDA Margin	22.14%	25.68%	354bps	23.56%	25.72%	216bps
Depreciation	49.56	45.41		49.57	45.43	
EBIT	107.90	159.05	47.41%	115.06	159.37	38.51%
EBIT Margin	15.17%	19.97%	480bps	16.47%	20.02%	355bps
Other Income	62.31	36.28		62.87	36.31	
Profit Before Tax (PBT after exceptional item)	170.21	195.33	14.76%	177.93	195.68	9.98%
Tax	42.99	52.52		43.32	52.81	
Profit After Tax (PAT)	127.22	142.81	12.25%	134.61	142.87	6.14%
PAT Margin	17.89%	17.94%	5bps	19.26%	17.94%	-132bps

9MFY22 – Profitability statement





DARTICIU ARS (# mln)	S	tandalone		C	onsolidated	
PARTICULARS (₹ mln)	9MFY21	9MFY22	% change	9MFY21	9MFY22	% change
Total Revenue	2,274.23	2,378.00	4.56%	2,277.50	2,381.85	4.58%
Direct Cost	88.67	93.17		91.53	90.31	
Gross Profit	2,185.56	2,284.83	4.54%	2,185.97	2,291.54	4.83%
Gross Margin	96.10%	96.08%	-2bps	95.98%	96.21%	23bps
Operating Cost						
Research and Development (R&D)	488.59	607.82		488.59	607.82	
Sales and Marketing (S&M)	482.74	571.23		494.71	580.23	
General Administration (G&A)	341.19	394.08		325.82	383.60	
Total Expenditure	1,312.52	1,573.13	-19.86%	1,309.12	1,571.65	-20.05%
EBITDA	873.04	711.70	-18.48%	876.85	719.89	-17.90%
EBITDA Margin	38.39%	29.93%	-846bps	38.50%	30.22%	-828bps
Depreciation	144.80	127.95		144.87	128.03	
EBIT	728.24	583.75	-19.84%	731.98	591.86	-19.14%
EBIT Margin	32.02%	24.55%	-747bps	32.14%	24.85%	-729bps
Other Income	182.13	135.12		184.27	135.33	
Profit Before Tax (PBT after exceptional items)	910.37	718.87	-21.04%	916.25	727.19	-20.63%
Exceptional items	0.00	21.64		-	-	
Profit Before Tax	910.37	697.23	-23.41%	916.25	727.19	-20.63%
Tax	242.81	175.33		243.71	176.21	
Profit After Tax (PAT)	667.56	521.90	-21.82%	672.54	550.98	-18.07%
PAT Margin	29.35%	21.95%	-741bps	29.53%	23.13%	-640bps

Q3FY22 – Ratio analysis



1 - 0/	Standalone		Consol	idated
In %	Q3FY21	Q3FY22	Q3FY21	Q3FY22
Expenses				
Direct Cost / Revenue	3.68%	4.07%	3.78%	4.07%
R&D / Revenue	23.91%	26.76%	24.34%	26.76%
S&M / Revenue	31.08%	26.57%	32.20%	26.98%
G&A / Revenue	19.18%	16.93%	16.12%	16.47%
Total Cost / Revenue	74.18%	70.25%	72.66%	70.21%
Margin				
Gross Margin	96.32%	95.93%	96.22%	95.93%
EBITDA	22.14%	25.68%	23.56%	25.72%
EBIT	15.17%	19.97%	16.47%	20.02%
PBT	23.93%	24.53%	25.46%	24.58%
PAT	17.89%	17.94%	19.26%	17.94%

9MFY22 – Ratio analysis



1 - 0/	Stand	Standalone		idated
In %	9MFY21	9MFY22	9MFY21	9MFY22
Expenses				
Direct Cost / Revenue	3.90%	3.92%	4.02%	3.79%
R&D / Revenue	21.48%	25.56%	21.45%	25.52%
S&M / Revenue	21.23%	24.02%	21.72%	24.36%
G&A / Revenue	15.00%	16.57%	14.31%	16.11%
Total Cost / Revenue	57.71%	66.15%	57.48%	65.98%
Margin				
Gross Margin	96.10%	96.08%	95.98%	96.21%
EBITDA	38.39%	29.93%	38.50%	30.22%
EBIT	32.02%	24.55%	32.14%	24.85%
PBT	40.03%	30.23%	40.23%	30.53%
PAT	29.35%	21.95%	29.53%	23.13%

Consolidated Balance Sheet





EQUITY AND LIABILITIES (₹ mln)	Dec 31, 2020	Dec 31, 2021
Share Holder's Funds:		
Equity Share Capital	642.05	579.55
Share application money pending allotment	-	-
Reserves and Surplus	6,472.75	5,373.69
Total Shareholder Funds	7,114.80	5,953.24
Non-Current Liabilities		
Net employee defined benefit liabilities	3.47	-
Other Non Current Liabilities	-	5.19
Deferred tax liability (net)	-	0.97
Total Non-Current Liabilities	3.47	6.16
Current Liabilities:		
Trade and Other Payables	493.01	526.61
Other Financial Liabilities	30.56	19.17
Other Current Liabilities	135.37	166.78
Net employee defined benefit liabilities	25.59	4.34
Current tax liabilities (Net)	14.18	0.86
Total Current Liabilities	698.71	717.76
Total Equity & Liabilities	7,816.98	6,677.16

	зесину этпринеи	1
ASSETS (₹ mln)	Dec 31, 2020	Dec 31, 2021
Non-Current Assets:		
Property, plant and equipment	1,408.76	1,330.27
Capital work-in-progress	34.00	2.44
Intangible assets	63.30	64.12
Non-current financial assets		
Investments in MF ,Tax-Free Bonds & others	174.04	247.48
Loan and Security Deposits	3.82	3.65
Bank Balances	3.40	-
Deferred tax assets (net)	12.49	-
Other non current assets	213.77	204.12
Total Non-Current Assets	1,913.58	1,852.08
Current assets:		
Inventories	32.88	37.41
Investment in Mutual Fund	3,945.08	2,595.89
Trade and other receivables	1,151.87	1,506.47
Bank Balances & Cash and Cash Equivalents	132.97	174.55
Investment in Fixed Deposit	576.63	446.40
Loan and security deposits	7.03	4.38
Interest accrued on FDR & Tax-Free Bonds	12.24	7.52
Other Current assets	44.70	46.92
Assets classified as held for sale	-	5.54
Total Current Assets	5,903.40	4,825.08
Total Assets	7,816.98	6,677.16

Standalone Balance Sheet





EQUITY AND LIABILITIES (₹ mln)	Dec 31, 2020	Dec 31, 2021
Share Holder's Funds:		
Equity Share Capital	642.05	579.55
Share application money pending allotment	-	-
Reserves and Surplus	6,512.10	5,388.85
Total Shareholder Funds	7,154.15	5,968.40
Non-Current Liabilities		
Net employee defined benefit liabilities	3.47	-
Other Non Current Liabilities	-	5.19
Deferred tax liability (net)	-	0.97
Total Non-Current Liabilities	3.47	6.16
Current Liabilities:		
Trade and Other Payables	490.83	530.00
Other Financial Liabilities	30.56	19.17
Other Current Liabilities	133.77	165.69
Net employee defined benefit liabilities	25.59	4.34
Current tax liabilities (Net)	13.91	0.71
Total Current Liabilities	694.66	719.91
Total Equity & Liabilities	7,852.28	6,694.47

	security simplified	1
ASSETS (₹ mln)	Dec 31, 2020	Dec 31, 2021
Non-Current Assets:		
Property, plant and equipment	1,408.53	1,329.96
Capital work-in-progress	34.00	2.44
Intangible assets	63.12	63.99
Non-current financial assets		
Investments in MF ,Tax-Free Bonds & others	296.32	348.12
Loan and Security Deposits	3.82	3.65
Bank Balances	3.40	-
Deferred tax assets (net)	12.49	-
Other non current assets	213.77	204.12
Total Non-Current Assets	2,035.45	1,952.28
Current assets:		
Inventories	32.66	37.38
Investment in Mutual Fund	3,945.08	2,595.89
Trade and other receivables	1,132.78	1,514.03
Bank Balances & Cash and Cash Equivalents	66.61	85.76
Investment in Fixed Deposit	576.63	446.40
Loan and security deposits	6.95	4.28
Interest accrued on FDR & Tax-Free Bonds	12.24	7.52
Other Current assets	43.88	45.39
Assets classified as held for sale	_	5.54
Total Current Assets	5,816.83	4,742.19
Total Assets	7,852.28	6,694.47


Working capital analysis



At the end of December, 2020*

At the end of September, 2021**

At the end of December, 2021*



Note*

Receivable Days = [(Debtors/ Sales) X (275 days)]

Inventory Days = [(Inventory/Sales) X (275 days)]

Payable Days = [(Creditor/Sales) X (275 days)]

Note**

Receivable Days = [(Debtors/ Sales) X (183 days)]

Inventory Days = [(Inventory/Sales) X (183 days)]


Payable Days = [(Creditor/Sales) X (183 days)]

Return ratio analysis



Return on Capital Employed*

Return on Equity*





- > Company is continuously evaluating strategic inorganic opportunities to invest across the cybersecurity ecosystem
- > Till such time the company invests its surplus cash in mutual funds, tax free-bonds and fixed deposits

RoCE = EBIT / Avg. Capital Employed (Equity + Debt)

Cash Adj. RoCE = EBIT / Avg. Cash Adj. Capital Employed (Equity + Debt – Cash & Cash Equivalents)

ROE = PAT / Avg. Equity





Thank You

Chief Financial Officer

Mr. Navin Sharma
Navin.Sharma@quickheal.co.in

Company Secretary

Mr. Srinivas Anasingaraju cs@quickheal.co.in +91-20-66813232

CIN No: L72200MH1995PLC091408

www.quickheal.co.in

Annexure



Products Sold in following countries

- Australia
- Bangladesh
- Benin
- Cambodia
- Canada
- Chile
- Colombia
- Congo
- Ecuador
- El Salvador
- France
- Gambia

- Germany
- Guinea
- Honduras
- Hong Kong
- Italy
- Japan
- Jordan
- Kenya
- Kuwait
- Macao
- Malaysia
- Mauritius

- Mexico
 - Morocco
 - Netherlands
 - New Zealand
 - Nigeria
 - Saudi Arabia
 - Singapore
 - Solomon Islands
 - South Africa
 - South Korea
 - Sri Lanka
 - Panama

- Paraguay
- Peru
- Philippines
- Qatar
- Rwanda
- Thailand
- Turkey
- Uganda
- UAE
- USA
- Venezuela

- Mumbai
- Pune

Chandigarh

New Delhi

Jaipur

Patna

Indore

Surat

Nashik

Nagpur

Lucknow

Guwahati

Ahmedabad

Sales & Support offices across India

- Aurangabad
- Kolhapur
- Raipur
- Kolkata
- Bhubaneshwar
- Hyderabad
- Bangalore
- Chennai
- Kochi

